Off-the-shelf CTX110 allogeneic CD19 CAR T shows responses in relapsed/refractory B-cell lymphoma, with manageable cytokine release syndrome.
|Articles|May 1, 1996
Supplements and Featured Publications
- Shifting Paradigms in the Treatment of Acid-Related Disorders
- Volume 2
- Issue 7 Suppl
Reflux Esophagitis/GERD
Advertisement
Articles in this issue
over 30 years ago
Duodenal/Gastric Ulcerover 30 years ago
Analysis: PPIs and H2RAsover 30 years ago
Interviewover 30 years ago
Selected Abstractsover 30 years ago
CME Quizover 30 years ago
Gastroesophageal Diseaseover 30 years ago
Introductionover 30 years ago
Goals and Objectivesover 30 years ago
Participating FacultyAdvertisement
Related to this article
David G. Mitchell, PharmD, MBA, CSP, FCPhA, of UC Davis Health, explains how AI-assisted prior authorizations have reduced denials and staff time without replacing pharmacist judgment.
Nearly half of working-age adults were inadequately insured in 2026, and half went without needed care due to cost, a Commonwealth Fund survey found.
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
A real-world trial found 42.6% of patients with severe hand eczema cleared on oral alitretinoin.
AMCP Nexus 2026 brings managed care leaders to San Diego October 26-29 to tackle Medicare negotiation, drug pricing policy, AI, and patient access.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
4
Managed Care Keeps Pace With Policy as AMCP Nexus Heads to San Diego
5